Freddy Jimenez, regional innovation lead for Pfizer in the Middle East, Africa, and Russia, is working to implement AI solutions for healthcare challenges in the UAE. Jimenez joined the Executive Education Program at MBZUAI to expand his knowledge and drive the country's healthcare industry forward. He emphasizes the importance of strategic approaches to AI in healthcare due to rapid technological advancements outpacing regulation. Why it matters: This highlights the UAE's focus on leveraging AI to improve healthcare outcomes and the importance of collaboration between industry, academia, and government to accelerate AI adoption in the heavily regulated healthcare sector.
KAUST Professor Pierre Magistretti participated in the U.S.-Saudi Arabia Business Leaders Virtual Forum, organized by the U.S. Chamber of Commerce and the Saudi Ministry of Investment. Magistretti spoke on a panel about healthcare innovation alongside representatives from Pfizer, Abbott, and the Saudi Ministry of Investment. KAUST's Smart-Health Initiative (SHI) aims to translate scientific discoveries into clinical tools. Why it matters: This participation highlights KAUST's growing role in shaping healthcare innovation within the Kingdom and fostering international collaborations in the field.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST and the International Medical Center (IMC) have signed an MoU to collaborate on medical research related to wellness, quality of life, and population health management. The partnership aims to develop AI applications for diagnosis and treatment, along with research in precision medicine and advanced therapies. The collaboration aligns with Saudi Vision 2030's goals to build a sustainable, knowledge-driven healthcare future. Why it matters: This agreement signifies a push to integrate AI and precision medicine into practical medical solutions within the Saudi healthcare system.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
The KAUST Smart-Health Initiative (KSHI) held its annual forum, showcasing research collaborations with partners like KFSHRC, KAIMRC, and KACST. Projects presented included biomarker detection devices, cardiovascular disease sensors, 3D data visualization, and genome sequencing for patient data analysis. Dr. Sara F. Althari highlighted KAUST's cultivation of partnerships within the Kingdom's healthcare and biotech ecosystem. Why it matters: The KSHI aims to transform Saudi Arabia's healthcare system towards precision and personalized medicine, aligning with Vision 2030.
KAUST Assistant Professor Dominik Michels received the first Procter & Gamble (P&G) Faculty Award for his research contributions to the consumer goods industry. Michels has a long-standing academic partnership with P&G, contributing to the development and integration of computer-aided product development techniques into P&G's workflow. The collaborative projects have focused on AI, machine learning, and scientific/visual computing. Why it matters: This award highlights KAUST's growing role in applied AI research and its successful partnerships with major global corporations, facilitating technology transfer and real-world impact.
KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.